Figure 5.

Evolution of first episode according to treatment. In children managed supportively, ERF did not develop; treatment with PEX was associated with a high rate of relapse if ERF did not occur, and ERF did not develop in any patient treated with eculizumab or no patient experienced relapse. No patient was treated with immunosuppression at the initial presentation. *Includes PEX alone (n = 8), PEX plus i.v. IgG (n = 2), PEX plus corticosteroids (n = 1). **Defined as recurrence >1 month after presentation and >15 days after disease remission. ^†One patient (patient 10) experienced multiple relapses and was maintained on regular PEX. ERF, established renal failure; PEX, plasma exchange.